Paraneoplastic Vision Loss Evaluation, Serum
Use
This test is useful for evaluating patients with rapidly progressive vision loss where a paraneoplastic cause, such as retinopathy or optic neuritis, is suspected. It is particularly relevant for patients with small-cell carcinoma who develop vision loss. Paraneoplastic vision loss can occur in association with autoantibodies like CRMP-5-IgG and recoverin, which are linked to occult small-cell carcinoma of the lung or other regions. Early diagnosis through this evaluation can help guide treatment options and improve clinical outcomes.
Special Instructions
This test should not be requested for patients who have recently received radioisotopes due to potential assay interference, and specimens will be screened for radioactivity before analysis. Optimal antibody detection is achieved when specimens are collected prior to the initiation of immunosuppressant medication.
Limitations
Negative results do not exclude the diagnosis of paraneoplastic eye disease. The test may be affected by interference from coexisting non-neuron-specific autoantibodies; serologic absorption is usually needed to eliminate these interferences.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
LOINC Codes
- 104992-3
- 72504-4
- 83003-4
- 104993-1
- 48767-8
Result Turnaround Time
8-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
4 mL
Minimum Volume
2 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial. Preferred container is a red top; serum gel is acceptable.
Patient Preparation
For optimal antibody detection, collect specimen prior to immunosuppressant medication initiation.
Causes for Rejection
Gross hemolysis, gross lipemia, and gross icterus are causes for rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |